Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Matulonis, Ursula A., Birrer, Michael J., Wright, Alexi A., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Curtis, Jennifer, Liu, Joyce F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712364/
https://www.ncbi.nlm.nih.gov/pubmed/31467965
http://dx.doi.org/10.1016/j.gore.2019.07.010
_version_ 1783446665183625216
author Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Matulonis, Ursula A.
Birrer, Michael J.
Wright, Alexi A.
Horowitz, Neil
Konstantinopoulos, Panagiotis A.
Curtis, Jennifer
Liu, Joyce F.
author_facet Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Matulonis, Ursula A.
Birrer, Michael J.
Wright, Alexi A.
Horowitz, Neil
Konstantinopoulos, Panagiotis A.
Curtis, Jennifer
Liu, Joyce F.
author_sort Lee, Elizabeth K.
collection PubMed
description Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies. Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.
format Online
Article
Text
id pubmed-6712364
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67123642019-08-29 Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer Lee, Elizabeth K. Tan-Wasielewski, Zhenying Matulonis, Ursula A. Birrer, Michael J. Wright, Alexi A. Horowitz, Neil Konstantinopoulos, Panagiotis A. Curtis, Jennifer Liu, Joyce F. Gynecol Oncol Rep Case Series Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies. Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer. Elsevier 2019-08-10 /pmc/articles/PMC6712364/ /pubmed/31467965 http://dx.doi.org/10.1016/j.gore.2019.07.010 Text en © 2019 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Series
Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Matulonis, Ursula A.
Birrer, Michael J.
Wright, Alexi A.
Horowitz, Neil
Konstantinopoulos, Panagiotis A.
Curtis, Jennifer
Liu, Joyce F.
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title_full Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title_fullStr Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title_full_unstemmed Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title_short Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
title_sort results of an abbreviated phase ib study of the hdac6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712364/
https://www.ncbi.nlm.nih.gov/pubmed/31467965
http://dx.doi.org/10.1016/j.gore.2019.07.010
work_keys_str_mv AT leeelizabethk resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT tanwasielewskizhenying resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT matulonisursulaa resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT birrermichaelj resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT wrightalexia resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT horowitzneil resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT konstantinopoulospanagiotisa resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT curtisjennifer resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer
AT liujoycef resultsofanabbreviatedphaseibstudyofthehdac6inhibitorricolinostatandpaclitaxelinrecurrentovarianfallopiantubeorprimaryperitonealcancer

Ejemplares similares